Response by Deharo et al to Letter Regarding Article, "Impact of Sapien 3 Balloon-Expandable Versus Evolut R Self-Expandable Transcatheter Aortic Valve Implantation in Patients With Aortic Stenosis: Data From a Nationwide Analysis".
Response by Deharo et al to Letter Regarding Article, "Impact of Sapien 3 Balloon-Expandable Versus Evolut R Self-Expandable Transcatheter Aortic Valve Implantation in Patients With Aortic Stenosis: Data From a Nationwide Analysis".
复制标题
Deharo 等人对有关文章“Sapien 3 球囊扩张型与 Evolut R 自扩张型经导管主动脉瓣植入对主动脉瓣狭窄患者的影响:来自全国范围分析的数据”的回复。
DOI:
10.1161/circulationaha.120.047271
复制
发表时间:
2020
期刊:
影响因子:
37.8
通讯作者:
L. Fauchier
中科院分区:
文献类型:
--
作者:
P. Deharo;A. Bisson;C. Saint Etienne;L. Fauchier
Circulation. 2020;141:e912–e913. DOI: 10.1161/CIRCULATIONAHA.120.047271 e912 Pierre Deharo, MD, PhD Arnaud Bisson, MD Christophe Saint Etienne, MD Laurent Fauchier , MD, PhD In Response: We read with attention the comments by Dr Abbas about our paper on the impact of balloon-expandable versus self-expandable transcatheter aortic valve implantation in French patients with aortic stenosis.1 We may agree with the general message that the clinical impact of echocardiographic gradients, areas, and leaks post–transcatheter aortic valve replacement (TAVR) is at best controversial, but this comment does not directly apply to our study. Our study was based on administrative data with information from diagnoses coded using International Classification of Diseases–10 and the French classification of medical procedures. Our analysis was restricted to the variables present in the database, which meant that echocardiography characteristics such as mean gradient, valve area, calcification, and paravalvular leak were not available for analysis, and we made no assumptions on the issues mentioned by Dr Abbas. Similarly, it is inappropriate to include our reference for a statement such as “echocardiographic gradient...does not translate into a clinically meaningful outcome with both older and newer generation devices” because we only included patients treated with newer generation devices (Evolut R and Sapiens 3). In our comments, we only proposed as a possible explanation that the higher risk of rehospitalization for heart failure with self-expandable valves might be related, among others, to a higher rate of paravalvular leak frequently reported by others with self-expandable valves.2,3 We agree that echography parameters after transcatheter aortic valve replacement implantation remain only surrogate end points to predict clinical outcomes. Our large population allowed us to analyze mortality, which is the ultimate end point after cardiac intervention. We would appreciate that our message remain as clear as possible. Our analysis included the largest cohort of latest-generation balloon-expandable versus self-expandable valves used for transcatheter aortic valve replacement. Balloon-expandable technology was associated with lower incidence rates of hard clinical end point (all-cause and cardiovascular death, and rehospitalization for heart failure), beyond the analysis of any echocardiographic end point. For what pertains to our study, it is inaccurate to state that our results were obtained “after adjusting for echocardiographic paravalvular leak and despite a residual higher gradient with balloon-expandable valves versus selfexpandable valves.”